Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20292631 | 0.98 | MEN1 (0.38) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL5960686 | 0.94 | — | — | |
| SCHEMBL8013405 | 0.84 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL9856963 | 0.82 | MEN1 (0.36) | MEN1KMT2AKDM4CL3MBTL1 | |
| SCHEMBL10693586 | 0.82 | MEN1 (0.36) | MEN1KMT2AKDM4CL3MBTL1 | |
| SCHEMBL9856958 | 0.82 | MEN1 (0.36) | MEN1KMT2AKDM4CL3MBTL1 | |
| SCHEMBL8545379 | 0.81 | MEN1 (0.43) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL19615983 | 0.80 | MEN1 (0.36) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL20159048 | 0.80 | MEN1 (0.36) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL979924 | 0.80 | MEN1 (0.36) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170080095-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2017-03-23 | — | — | US | disclosed |
| US-9328075-B2 | Pyrimidinone compounds and methods for treating influenza | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328075-B2 | Pyrimidinone compounds and methods for treating influenza | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012151567-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-1007035-A4 | POLYTHIOPHENE ANTI-TUMOR AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2000-11-22 | — | — | EP | disclosed |
| EP-0745073-B1 | 5-SUBSTITUTED DERIVATIVES OF MYCOPHENOLIC ACID | SYNTEX INC (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-1007035-A1 | POLYTHIOPHENE ANTI-TUMOR AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998023269-A1 | POLYTHIOPHENE ANTI-TUMOR AGENTS | PURDUE RESEARCH FOUNDATION (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5493030-A | CHEMICAL INTERMEDIATES | SYNTEX (U.S.A.) INC. (US) | 1996-02-20 | — | — | US | disclosed |
| WO-1995022538-A1 | 5-SUBSTITUTED DERIVATIVES OF MYCOPHENOLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| WO-1995022534-A1 | 4-AMINO 6-SUBSTITUTED MYCOPHENOLIC ACID AND DERIVATIVES WITH IMMUNOSUPPRESSIVE ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| WO-1995022537-A2 | 4-AMINO DERIVATIVES OF 5-SUBSTITUTED MYCOPHENOLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| WO-1995022536-A1 | 6-SUBSTITUTED MYCOPHENOLIC AND DERIVATIVES WITH IMMUNOSUPPRESSIVE ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| US-5444072-A | Useful in treatment of autoimmune disorders, psoriasis, inflammatory diseases, rheumatoid arthritis | SYNTEX (U.S.A.) INC. (US) | 1995-08-22 | — | — | US | disclosed |
| EP-0532423-A1 | Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0104468-B1 | ARACHIDONIC ACID ANALOGUES AS ANTI-INFLAMMATORY AND ANTIALLERGIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1986-07-23 | — | — | EP | disclosed |
| US-4497827-A | TETRAZOLE, ACYLHYDROXYLAMINE, HYDROXYMETHYLKETONE AND AMIDE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1985-02-05 | — | — | US | disclosed |
| EP-0104468-A1 | Arachidonic acid analogues as anti-inflammatory and antiallergic agents | SYNTEX (U.S.A.) INC. (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080095-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | ABCB4, LNPK, MBOAT1 | MEN1 1713/4885KMT2A 3750/4885KDM4C 4645/4885 |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ADA, TYMP, ITPA | MEN1 1902/4885KMT2A 2664/4885KDM4C 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.